Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
CHAPEL HILL, N.C., Feb. 29, 2016 -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the 36th Annual Cowen and Company Healthcare Conference. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, is scheduled to present at 2:40 p.m. ET on Monday, March 7, 2016, at the Marriot Copley Place in Boston.
A live audio webcast and archive of the presentations will be available on the company website at http://investor.cempra.com/events.cfm. Listeners are encouraged to visit the site prior to the scheduled presentation to register, download and install any necessary audio software.
About Cempra, Inc.
Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) has successfully completed two Phase 3 clinical trials for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin is also in a Phase 3 clinical trial for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia. Cempra is contracted with BARDA for the development of solithromycin for pediatric use. Three formulations, intravenous, oral capsules and a suspension formulation are in a Phase 1b trial in children from birth to 17 years of age. Taksta™ is Cempra's second product candidate, which is being developed for acute bacterial skin and skin structure Infections (ABSSSI) and is also expected to be tested in an exploratory study for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit www.cempra.com.
Contacts: Investor Contact: Robert H. Uhl Westwicke Partners, LLC (858) 356-5932 [email protected] Media Contact: Tony Plohoros 6 Degrees (908) 591-2839 [email protected]
